| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2388822A1 27 human secreted proteins |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387613A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them |
| 05/10/2001 | CA2387261A1 25 human secreted proteins |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2383992A1 Antibiotic sultam and sultone derived oxazolidinones |
| 05/10/2001 | CA2289315A1 Compositions expressing a pressure of carbon dioxide for improved healing of wounds |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097712A1 Steroid-containing cataplasms and process for producing the same |
| 05/09/2001 | EP1097711A2 Treatment of pulmonary hypertension |
| 05/09/2001 | EP1097696A1 Composition containing waxes and an hydrophilic active unstable in an oxidizing medium and cosmetic use thereof |
| 05/09/2001 | EP1097241A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 05/09/2001 | EP1097200A1 Pharmaceutical uses of nab1 and nab2 |
| 05/09/2001 | EP1097168A2 Compounds and methods for modulating cadherin-mediated functions |
| 05/09/2001 | EP1097159A1 Phosphinous and phosphonic acid derivatives used as medicaments |
| 05/09/2001 | EP1097147A1 Novel angiogenesis inhibitors |
| 05/09/2001 | EP1097139A1 Quinoline derivatives |
| 05/09/2001 | EP1096945A1 Lysine binding fragments of angiostatin |
| 05/09/2001 | EP1096944A1 Extracts of zanthoxylum bungeanum, pharmaceutical and cosmetic formulations containing them |
| 05/09/2001 | EP1096938A1 Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide |
| 05/09/2001 | EP1096924A1 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 05/09/2001 | EP1096918A2 Skin and tissue care and/or treatment agent |
| 05/09/2001 | EP0450040B1 Pharmaceutical and cosmetic depigmentation compositions with a caffeic acid base |
| 05/09/2001 | CN1294632A Compsns. derived from i(mycobacterium vaccae) and methods for their use |
| 05/09/2001 | CN1294587A Benzo [B] pyran derivatives useful as external agents for skin |
| 05/09/2001 | CN1293993A Styptic and inflammation-relieving medicine and its preparing process |
| 05/09/2001 | CN1293977A Medicinal composition for treating psoriasis and its preparing process |
| 05/09/2001 | CN1293968A Coptis liquid for relieving inflammation and moistening skin and its preparing process |
| 05/09/2001 | CN1293953A 'Xianketie' medicine for treating tinea |
| 05/09/2001 | CN1065438C Cyclic adhesion inhibitors |
| 05/09/2001 | CN1065435C Improved external-use medicine having efficient and low by-effect for treating seborrheic baldness |
| 05/09/2001 | CN1065434C External-use medicine for treating skin disease |
| 05/09/2001 | CN1065430C Wart curing paste |
| 05/09/2001 | CN1065428C Matrix type patch preparations |
| 05/08/2001 | US6229025 Process for alkylating hindered sulfonamides |
| 05/08/2001 | US6229016 Method for treating tumors using 2-aryl-naphthyridin-4-ones |
| 05/08/2001 | US6229013 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 05/08/2001 | US6228889 Methods for treatment of conditions associated with lactosylceramide |
| 05/08/2001 | US6228853 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 05/08/2001 | US6228834 Treating gramnegative bacterial infections; neutralizing lipopolysaccharides |
| 05/08/2001 | US6228642 Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| 05/08/2001 | US6228619 Glucosaminidase |
| 05/08/2001 | US6228617 Nucleotide sequence coding a trigger chaperone protein; for use in screening bactericides |
| 05/08/2001 | US6228380 Delivery of hydroxy carboxylic acids |
| 05/08/2001 | US6228350 Method of depigmenting and/or bleaching skin and/or body hair or head hair |
| 05/08/2001 | CA2065412C Methods of preventing and reducing the size of striae distensae lesions |
| 05/08/2001 | CA2029694C Heteroatoms-containing tricyclic compounds |
| 05/03/2001 | WO2001031051A2 Antisense modulation of protein kinase c-theta expression |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031016A2 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | WO2001030978A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | WO2001030844A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | WO2001030801A1 Antisense modulation of integrin-linked kinase expression |
| 05/03/2001 | WO2001030784A1 Silicon compounds derived from ascorbic acid |
| 05/03/2001 | WO2001030781A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
| 05/03/2001 | WO2001030777A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | WO2001030774A1 Substituted indoles for modulating nfkb activity |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030754A2 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030389A1 Wound contraction inhibitors |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030367A1 Platelet-activating factor antagonists and dermatological compositions for external use containing the same |
| 05/03/2001 | WO2001030363A1 A procedure for obtaining a zinc oxide containing product for skin-healing, care and protection in children and adults |
| 05/03/2001 | WO2001030362A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030313A1 Cosmetic compositions containing mulberry extract and retinoids |
| 05/03/2001 | WO2001030300A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | WO2001030151A1 Methods of treating hair loss comprising administering indoline compound |
| 05/03/2001 | WO2000074712A3 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 05/03/2001 | WO2000072876A3 Prevention and treatment of amyloidogenic disease |
| 05/03/2001 | DE19952147A1 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New cyclopropanes, pharmaceutical compositions containing them and methods for their preparation |
| 05/03/2001 | DE19951970A1 Arzneimittel für die Toleranzinduktion Medicines for tolerance induction |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2389031A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | CA2388974A1 Medicament in order to induce tolerance |
| 05/03/2001 | CA2388934A1 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | CA2388924A1 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | CA2388338A1 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | CA2388313A1 Silicon compounds derived from ascorbic acid |
| 05/03/2001 | CA2388121A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | CA2388119A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | CA2387506A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | CA2387378A1 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | CA2386889A1 Methods of treating hair loss comprising administering indoline compound |
| 05/03/2001 | CA2385929A1 Use of gdnf for treating corneal defects |
| 05/02/2001 | EP1096016A1 Platelet-activating factor acetylhydrolase |
| 05/02/2001 | EP1096008A2 Human G protein-coupled receptor, PFI-014 |
| 05/02/2001 | EP1095660A2 Therapeutic combination containing terpinen-4-ol and medicinal plants |
| 05/02/2001 | EP1095159A1 Bone morphogenic protein |
| 05/02/2001 | EP1095140A2 Neurotrophic factors |
| 05/02/2001 | EP1095062A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 05/02/2001 | EP1095057A1 Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof |